Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
- Pasi A. Jänne
- , Yasushi Goto
- , Toshio Kubo
- , Kiichiro Ninomiya
- , Sang We Kim
- , David Planchard
- , Myung Ju Ahn
- , Egbert Smit
- , Adrianus Johannes de Langen
- , Maurice Pérol
- , Elvire Pons-Tostivint
- , Silvia Novello
- , Hidetoshi Hayashi
- , Junichi Shimizu
- , Dong Wan Kim
- , Kaline Pereira
- , Fu Chih Cheng
- , Ayumi Taguchi
- , Yingkai Cheng
- , Kyle Dunton
- Dana-Farber Cancer Institute
- National Cancer Center Japan
- Okayama University
- University of Ulsan
- Université Paris-Saclay
- Leiden University
- Netherlands Cancer Institute
- Centre Léon Bérard
- Nantes University
- Azienda Ospedaliera S. Luigi Gonzaga
- Kindai University
- Aichi Cancer Center Hospital and Research Institute
- Seoul National University
- Daiichi Sankyo Company, Limited
- Daiichi Sankyo UK Ltd
- Global Oncology Clinical Development
Research output: Contribution to journal › Article › peer-review
42
!!Link opens in a new tab
Scopus
citations